Self insured company works with metabolic researchers to use TCF (total carbohydrate restriction / keto) and IF (intermittent fasting) to reduce their health care cost of chronic metabolic issues.
41 completed the one-year intervention. Mean weight loss for the 50 subjects in the intention-to-treat analysis was 19.5 ± 11.4 kg, corresponding to 15.5% total body weight loss with concomitant deprescription of 96 medications, while starting only 8 medications. In patients who discontinued GLP-1 receptor agonists, weight loss continued or was maintained. Annualized cost savings from the TOWARD approach were approximately -$1700 per patient, as compared to an annualized cost burden of roughly +$13000 per patient for a GLP-1 receptor agonist.
Full Paper https://doi.org/10.3389/fnut.2025.1548609
